Pompe Disease Therapeutics and Treatment Market Report 2024

"The Business Research Company recently released a comprehensive report on the Global Pompe Disease Market Size and Trends Analysis with Forecast 2024-2033. This latest market research report offers a wealth of valuable insights and data, including global market size, regional shares, and competitor market share. Additionally, it covers current trends, future opportunities, and essential data for success in the industry.

Ready to Dive into Something Exciting? Get Your Free Exclusive Sample of Our Research Report @
https://www.thebusinessresearchcompany.com/sample.aspx?id=11906&type=smp

According to The Business Research Company's, The pompe disease market size has grown steadily in recent years. It will grow from $1.66 billion in 2023 to $1.73 billion in 2024 at a compound annual growth rate (CAGR) of 4.2%. The growth in the historic period can be attributed to increased awareness and diagnosis, orphan drug designation and incentives, global collaborations and research initiatives, patient advocacy and support groups..

The pompe disease market size is expected to see strong growth in the next few years. It will grow to $2.13 billion in 2028 at a compound annual growth rate (CAGR) of 5.3%. The growth in the forecast period can be attributed to continued research and development, expansion of newborn screening programs, advancements in gene therapy, increasing global investment in rare diseases, patient-centric drug development, expansion of clinical trials and research initiatives, market emphasis on personalized medicine approaches. Major trends in the forecast period include product innovation, technological advancements, implementation of patient support programs, growing adoption of telemedicine for patient management, collaborations for expanded access programs..

Get The Complete Scope Of The Report @
https://www.thebusinessresearchcompany.com/report/pompe-disease-global-market-report

Market Drivers and Trends:

The increase in the prevalence of pompe disease is expected to propel the growth of the pompe disease market. Pompe disease, also known as glycogen storage disease type II or acid maltase deficiency, is a rare genetic disorder characterized by the build-up of glycogen (a complex sugar molecule) in various body tissues, particularly in muscles and organs. Treatments for pompe disease include protein replacement therapy, alglucosidase alfa, and Nexviazyme for intravenous infusion. A rise in pompe disease cases will contribute to the growth of the pompe disease market. For instance, in June 2022, according to the European Medicines Agency Highlights, a Europe-based intergovernmental organization, there are roughly 224 infantile-onset, 471 juvenile-onset, and 20,490 adult-onset persons in Europe with mutations that potentially cause Pompe disease based on the maximum birth incidence of 11.6 per 100,000. Therefore, the increase in the prevalence of pompe disease is driving the growth of the pompe disease market.

Product innovations are a key trend gaining popularity in the pompe disease market. Major companies operating in the pompe disease market are adopting innovations to sustain their position in the market. For instance, in September 2023, Amicus Therapeutics, a US-based biopharmaceutical company, received approval from the U.S. Food and Drug Administration (FDA) for Pombiliti (cipaglucosidase alfa-atga) and Opfolda (miglustat) 65 mg capsules. This two-component therapy is designed for adults with late-onset Pompe disease (LOPD) weighing =40 kg. Pombiliti and Opfolda are a unique combination, with Pombiliti being a recombinant human GAA enzyme (rhGAA) designed for increased uptake into muscle cells and Opfolda serving as an enzyme stabilizer to stabilize the enzyme in the blood. This FDA approval underscores the significance of advancements in science and medicine.

Key Benefits for Stakeholders:

• Comprehensive Market Insights: Stakeholders gain access to detailed market statistics, trends, and analyses that help them understand the current and future landscape of their industry.
• Informed Decision-Making: The reports provide crucial data that support strategic decisions, reducing risks and enhancing business planning.
• Competitive Advantage: With in-depth competitor analysis and market share information, stakeholders can identify opportunities to outperform their competition.
• Tailored Solutions: The Business Research Company offers customized reports that address specific needs, ensuring stakeholders receive relevant and actionable insights.
• Global Perspective: The reports cover various regions and markets, providing a broad view that helps stakeholders expand and operate successfully on a global scale.

Major Key Players of the Market:

F. Hoffmann-La Roche AG, Bayer AG, Novartis AG, Sanofi S.A., Thermo Fisher Scientific Inc., Fresenius Kabi AG, Danaher Corporation, Becton, Dickinson and Company, Astellas Pharma Inc., BioMérieux SA, BioMarin Pharmaceutical Inc., Nova Biomedical Corporation, Instrumentation Laboratory Company, Amicus Therapeutics Inc., Sekisui Diagnostics LLC, Spark Therapeutics Inc., Sangamo BioSciences Inc., Asklepios BioPharmaceutical Inc., Avrobio Inc., EKF Diagnostics Holdings plc, Trinity Biotech plc, Chembio Diagnostics Inc., Audentes Therapeutics Inc., Rougine Darou, Genethon, Maze Therapeutics Inc., Avidity Biosciences Inc., EpiVax Inc., M6P Therapeutics, Oxyrane UK Limited, Valerion Therapeutics LLC

Pompe Disease Market 2024 Key Insights:

• The pompe disease market size is expected to see strong growth in the next few years. It will grow to $2.13 billion in 2028 at a compound annual growth rate (CAGR) of 5.3%.
• Rising Prevalence Of Pompe Disease Fuels Market Expansion
• Innovative Therapies Transforming Pompe Disease Market Dynamics
• North America was the largest region in the pompe disease market in 2023

We Offer Customized Report, Click @
https://www.thebusinessresearchcompany.com/Customise?id=11906&type=smp

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company

The Business Research Company (www.thebusinessresearchcompany.com) is a leading market intelligence firm renowned for its expertise in company, market, and consumer research. With a global presence, TBRC's consultants specialize in diverse industries such as manufacturing, healthcare, financial services, chemicals, and technology, providing unparalleled insights and strategic guidance to clients worldwide.

This release was published on openPR.